Freefall Accelerates at Judges Scientific PLC

Growth slows and the shares plummet; is Judges Scientific PLC (LON: JDG) worth buying now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Those holding one-time private-investor darling Judges Scientific (LSE: JDG) woke up to a nasty shock this morning as the shares opened around 30% lower. As I write, they’ve bounced back a bit and now sit about 17% down from last night’s close, at 1460p.

The AIM-listed firm specialises in the design and production of scientific instruments. Rapid expansion through both organic and acquisitive growth saw the company delight investors as the share price climbed from circa 400p as 2012 kicked off, to top out at about 2400p in the spring of 2014 after sextupling investor’s money — it’s the kind of investing result we all dream of, but subsequent events provide something of salutary lesson for those active in the small-cap space.

Rapid falls can follow rapid rises

Since flirting with the heights, the firm’s shares are down about 38% this year as the pace of forward earnings’ growth slowed. It seems a particular problem with small-cap investing: momentum can carry the shares too high, and valuations often become stretched. Judges Scientific traded on a historic P/E rating approaching 24 at around 2400p, which looks high compared to forward earnings’ growth predictions in single figures.

For that reason, it pays to be nimble in the world of small caps. If valuations get high and we find ourselves with a big capital gain, we should sell up and bank it, or sell a good proportion of it at least, rather than hang on for even more gains. Let’s be clear about this, selling to lock in gains is good risk management and a valid reason for reaching a sell decision. Selling because of profit is what made the likes of Warren Buffett, Peter Lynch and Jesse Livermore rich. It’s why we buy shares in the first place, to sell at a profit. Don’t be caught up in woolly notions of distinguishing between being an investor over being a trader; it’s all the same thing. Being a winner in the stock market is what counts.

Pedestrian profit growth

Today’s announcement from the company updates about H1 trading, which the directors describe as challenging. Nonetheless, revenue growth of 43% over the year-ago figure sounds encouraging, but includes the results from an acquisition made on 26 June 2013. Without that acquisition, the firm delivered a less startling 3.2% organic growth over the period.

Organic order intake over the six-month period was 4.8% below last year and, overall, orders were 11% below the level required to meet the firm’s sales budget for the year. The order book represents 7.8 weeks of sales, compared to 10.6 weeks a year ago. The directors cite government efforts to contain public sector spending and a 10% appreciation of Sterling against the US dollar during the last 12 months as contributors to the firm’s headwinds.

What now?

After seeing the fun enjoyed by Judges Scientific holders, it’s tempting to ask whether the firm is presenting investors with a chance for a second bite of the cherry now. I reckon it might be. After all, growth is down but not out, and you can’t fault the director’s track record of value delivery as the firm’s earnings rose by about 260% over the last four years.

I wouldn’t bet against management’s knack for pulling off carefully targeted value-enhancing acquisition deals or growing what seems to be a sound business organically. However, I do think forward growth could be slower than what we’ve seen recently, so investors will look for a lower rating.

Right now, the shares trade on a comfortable-looking historical P/E rating of about 14, which makes Judges Scientific a good candidate for further research, in my book.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool has no position in any of the shares mentioned.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »